Moazzam Shahzad, MD

Cancer Focus:
Esophageal Cancer, Gastrointestinal Carcinoid Tumor, Kidney (Renal Cell) Cancer, Liver (Hepatocellular) Cancer, Lung Cancer, Prostate Cancer, Testicular Cancer

Dr. Shahzad received his MBBS degree from Allama Iqbal Medical College, University of Health Sciences, Lahore, Pakistan. He completed an Internal Medicine Residency at One Brooklyn Health/Interfaith Medical Center, Brooklyn, New York, followed by a Hematology-Oncology Fellowship at the University of South Florida, Morsani College of Medicine, and Moffitt Cancer Center.

Dr. Shahzad’s clinical interests focus on delivering high-quality cancer care, with a particular emphasis on solid tumors and integrating evidence-based practices to improve patient outcomes, along with expanding access to novel therapies through clinical trial participation in underserved populations. His research interests focus on clinical trial development and real-world outcomes to improve care delivery, with emphasis on addressing disparities and advancing global oncology through collaborative efforts.

• Shahzad M, Amin MK, Gandicheruvu H, Kasaeian A, Khan A, McGuirk M, Pfannenstiel K, Habib A, Hamadani M, Abbyankar S, McGuirk J, Mushtaq MU. Impact of CD34+ Graft Cell Dose on Outcomes after Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis. Transplant Cell Ther. 2026 May. Pubmedid: 42114810.
• Maqbool S, Khan I, Ibrahim M, Thida AM, Faisal MS, Faraz F, Khan A, Shahzad M, Rehman MEU, Muhammad QUA, Rehman A. Efficacy and safety profile of busulfan plus low-dose melphalan (BUMEL) versus high-dose melphalan (MEL200) as a conditioning regimen for autologous hematopoietic stem cell transplantation (auto-HSCT) in multiple myeloma patients: a systematic review and. Expert Rev Hematol. 2026 Jun.19(6):641-651. Pubmedid: 41860155.
• Shahzad M, Amin MK, Kasaeian A, Tariq SM, Oskouie IM, Akram U, Aziz N, Warraich SZ, Khalid MF, Anwar I, Mushtaq MU, Jaglal M. Outcomes With Immunotherapy in Hormone Receptor-Positive Breast Cancer: A Systematic Review and Meta-Analysis. Am J Clin Oncol. 2026 Jun.49(6):297-307. Pubmedid: 42138278.
• Basharat A, Mannan MS, Shabbir MR, Khan MW, Basit T, Park R, Chadha J, Shahzad M. Transient PSA Suppression Without Survival Benefit: Real-World Comparative Effectiveness of Cabazitaxel Plus Carboplatin in Metastatic Castration-Resistant Prostate Cancer (mCRPC). Clin Genitourin Cancer. 2026 Jul.24(6):102625. Pubmedid: 42556088.
• Mushtaq MU, Amin MK, Kasaeian A, Patan S, Rehman AU, Zaheer A, Sayali FO, Rukh S, Ma'koseh M, Singh AK, Hamadani M, Mcguirk JP, Shahzad M. Outcomes of Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis in Acute Myeloid Leukemia and Myelodysplastic Syndromes Patients Over 70 Years of Age: A Comparative Analysis by Age Group. Clin Lymphoma Myeloma Leuk. 2026 Jul.26(7):e906-e914.e8. Pubmedid: 42168078.
• Shahzad M, Amin MK, Javed HMH, Kasaeian A, Sattar Z, Zeidkilani J, Oskouie IM, Irfan S, Sehar R, Warraich SZ, Mushtaq MU, Jaglal M. Vitamin C as an Adjunctive Therapy in Cancer: A Systematic Review and Meta-Analysis of Outcomes in Solid and Hematologic Malignancies. Am J Clin Oncol. 2026 Jul. Pubmedid: 42507830.
• Mannan MS, Musheer A, Basharat A, Sial F, Khan MW, Al-Sadi A, Amin MK, Shahzad M. Outcomes of Epidermal Growth Factor Receptor Inhibitors in Locally Advanced and Metastatic Anal Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis. J Gastrointest Cancer. 2026 Jul.57(1). Pubmedid: 42397650.
• Akram U, Nadeem ZA, Rehman OU, Raza MA, Nadeem A, Abdul Rehman K, Kareem R, Zahid M, Fatima E, Ashraf H, Ashfaq H, Amin MK, Shahzad M. Efficacy and Safety of Camrelizumab Combination Therapy in Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis. Am J Clin Oncol. 2026 Jan. Pubmedid: 41589607.
• Shahzad M, Amin MK, Irfan S, Ahsan R, Qasim H, Javed MJ, McGuirk M, Chaudhary SG, Anwar I, Yacoub A, Singh AK, Hamadani M, Mcguirk JP, Mushtaq MU. Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients Aged 65 Years and Above With Myelofibrosis. Clin Lymphoma Myeloma Leuk. 2026 Jan.26(1):e32-e40. Pubmedid: 40930937. Pmcid: PMC12924662.
• Shahzad M, Amin MK, Irfan S, Vyas A, Ahsan R, Chaudhary SG, Anwar I, McGuirk M, Iftikhar R, Abdelhakim H, Singh AK, Hamadani M, Mcguirk JP, Mushtaq MU. Impact of Measurable Residual Disease Status on Outcomes After HLA-Matched Donor Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2026 Jan.26(1):e23-e31. Pubmedid: 40930936.
• Amin MK, Shahzad M, Khan A, Begiashvili V, Khan U, McGuirk M, DeJarnette S, Chaudhary SG, Anwar I, Ahmed N, Abdallah AO, Abhyankar SH, McGuirk JP, Singh AK, Mushtaq MU. Outcomes after bone marrow versus peripheral blood haploidentical hematopoietic cell transplantation using post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis. Hematol Transfus Cell Ther. 2026 Feb.48(1):106222. Pubmedid: 41313884. Pmcid: PMC12702007.
• Musheer A, Mannan MS, Khan MW, Junaid A, Basit T, Hafeez AS, Shahzad M. Durvalumab Consolidation After Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Efficacy and Safety. Am J Clin Oncol. 2026 Aug. Pubmedid: 42574292.
• Amin MK, Shahzad M, Gandicheruvu H, Noor N, Khan U, Kasaeian A, Rukh S, Abdelhakim H, Lakkaraja M, Hamadani M, McGuirk J, Mushtaq MU. Impact Of Conditioning Intensity on Outcomes After Unrelated Donor Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis. Transplant Cell Ther. 2026 Aug. Pubmedid: 42665019.
• Mushtaq MU, Kasaeian A, Rostami T, Amin MK, Forghani S, Alemi H, Khavandgar N, Rukh S, Halahleh K, Singh AK, Abdallah AO, Hamadani M, McGuirk JP, Shahzad M. Outcomes after Matched Sibling Donor versus Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis. Transplant Cell Ther. 2026 Aug. Pubmedid: 42612728.
• Musheer A, Mannan MS, Khan MW, Junaid A, Iqra, Hafeez AS, Kazmi ZH, Iqbal A, Butt AR, Faisal N, Haider ST, Shahzad M. Blinatumomab versus chemotherapy in pediatric B-ALL: A meta-analysis of randomized trials in relapsed and high-risk frontline disease. Curr Prob Cancer. 2026 Aug.64:101328. Pubmedid: 42541895.
• Amin MK, Noor N, Maqsood MT, Ali H, Ahmad H, Memon H, Iqbal F, Ishtiaq S, Zamir M, Shaukat M, Habib A, Shahzad M, Hamadani M, McGuirk J, Mushtaq MU. Long-Term Gynecologic and Reproductive Health in Female Survivors of Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-analysis of Prevalence. Transplant Cell Ther. 2026 Aug.32(8):942.e1-942.e4. Pubmedid: 42128296.
• Lee WJ, Asghar MS, Park R, Won SH, Shahzad M, Shimshak T. Externally Validated Machine Learning Models for 30-/90-/180-Day Unplanned Readmission After Head and Neck Cancer Hospitalizations in the United States. JCO Clin Cancer Inform. 2026 Apr.10(2):e2500335. Pubmedid: 42284547. Pmcid: PMC13268123.
• Shahzad M, Mohsin A, Khamees I, Rehman AU, Amin MK, Chaudhary SG, Anwer I, Pfannenstiel K, Abdallah AO, Hamadani M, Mcguirk JP, Mushtaq MU. Impact of body mass index on outcomes following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2025 Oct.60(10):1390-1393. Pubmedid: 40676174.
• Shahzad M, Amin MK, Nelson M, Vyas A, Al-Ramahi JS, Ahmed N, Bansal R, Abdelhakim H, Shune L, Abdallah AO, Singh AK, Abhyankar SH, McGuirk JP, Mushtaq MU. Concurrent intravenous immunoglobulin and platelet transfusion for refractory alloimmune thrombocytopenia in patients undergoing allogeneic hematopoietic stem cell transplantation. Hematol Transfus Cell Ther. 2025 Oct.47(4):103961. Pubmedid: 40789261. Pmcid: PMC12356998.
• Ullah A, Haider F, Ahmed F, Arham M, Dad A, Tareen H, Saleem F, Bakht K, Malik AN, Afzaal Z, Athar FB, Aman K, Zahid H, Asjid M, Ejaz S, Qureshi Z, Shahzad M. Comparative safety and efficacy of tislelizumab-based regimens versus chemotherapy in lung cancer: a systematic review and meta-analysis. Front Oncol. 2025 Oct.15:1628742. Pubmedid: 41127016. Pmcid: PMC12537389.
• Shahzad M, Amin MK, Aziz N, Tariq SM, Warraich SZ, Jaglal M. Liquid biopsy and health-related quality of life in cancers: a systematic review. Support Care Cancer. 2025 Nov.33(12):1083. Pubmedid: 41254449.
• Shahzad M, Javed HMH, Mannan MS, Mushtaq MU. Outcomes with imetelstat in myelofibrosis: a systematic review and meta-analysis. Leuk Lymphoma. 2025 Dec.66(14):2708-2716. Pubmedid: 41090485.
• Ahmed S, Ashraf H, Ashfaq H, Ahmad E, Akram U, Ali A, Ahmad S, Ahmed R, Amin MK, Shahzad M. Trends and disparities in immune thrombocytopenic purpura-related mortality in the United States: a retrospective study over 24 years. Hematology. 2025 Dec.30(1):2559334. Pubmedid: 40955623.
• Aziz N, Nabi W, Umer HM, Khan F, Habib H, Musheer A, Makhkamov S, Nahidi SM, Memon RS, Anwer F, Shahzad M. Impact of Thrombopoietin Receptor Agonists on Platelet Transfusion Requirements in Myelodysplastic Syndromes: An Updated Systematic Review and Meta-Analysis. Clin Lymphoma Myeloma Leuk. 2025 Dec.25(12):e1065-e1076. Pubmedid: 40883154.
• Shahzad M, Amin MK, Badar T. Upfront Immunotherapy Approaches in the Management of Adults with Acute Lymphoblastic Leukemia. Cancers (Basel). 2025 Aug.17(17). Pubmedid: 40940843. Pmcid: PMC12427397.
• Rehman AU, Ayoobkhan FS, Shahzad M, Amin MK, Shatnawi S, Irfan S, Chaudhary SG, Anwer F, McGuirk JP, Mohty M, Ahmed N, Abdallah AO, Mushtaq MU. Attitudes and perspectives of oncologists about measurable residual disease testing in multiple myeloma: initiative for standardizing guidelines. Bone Marrow Transplant. 2025 Aug.60(8):1169-1174. Pubmedid: 40325139.
• Badar T, Shahzad M, Atallah E, Litzow MR, Kharfan-Dabaja MA. Transplant or no transplant for TP53 mutated AML. Oncotarget. 2024 Oct.15:674-676. Pubmedid: 39352794. Pmcid: PMC11444334.
• Anwar A, Amin MK, Anwar S, Shahzad M. Bridge the Gap: Addressing Rural End-of-Life Care Disparities and Access to Hospice Services. J Pain Symptom Manag. 2024 Oct.68(4):e280-e286. Pubmedid: 39002712.
• Yu J, Park R, Miao R, Imanirad I, Shahzad M, Laborde JM, Knepper TC, Walko CM, Kim R. Blood Tumor Mutational Burden Alone Is Not a Good Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Patients With Gastrointestinal Tumors. J Immunother. 2024 Nov.47(9):378-383. Pubmedid: 39012081.
• Shahzad M, Khalid MF, Amin MK, Basharat A, Ammad-Ud-Din M, Park R, Anwar I, Faisal MS, Jaglal M. Geographic and Racial Disparities in Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials Access for Diffuse Large B-Cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2024 May.24(5):316-322. Pubmedid: 38342727.
• Shahzad M, Khalid MF, Amin MK, Ammad-Ud-Din M, Ilyas U, Mushtaq AH, Butt A, Anwar I, Chaudhary SG, Ahmed N, Shune L, Singh AK, Abhyankar SH, McGuirk JP, Mushtaq MU. Use of Endpoints in Phase III Randomized Controlled Trials for Hematopoietic Stem Cell Transplantation Over the Last 15 Years: A Systematic Review. Hematol Oncol Stem Cell Ther. 2024 Mar.17(2):88-94. Pubmedid: 38560970.
• McGuirk M, Shahzad M, Amin MK, Khan MA, Bellman P, Mudaranthakam DP, DeJarnette S, Lutfi F, Ahmed N, Bansal R, Abdelhakim H, Gorsline C, Shoemaker DM, Abdallah AO, Shune L, Abhyankar SH, Singh AK, McGuirk JP, Mushtaq MU. Predictors of cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: Insights from a real-world experience. Transpl Immunol. 2024 Jun.84:102039. Pubmedid: 38513813.
• Al-Ramahi JS, Shahzad M, Nguyen A, Li K, Amin MK, Ahmed N, Lutfi F, DeJarnette S, Chaudhary SG, Bansal R, Abdelhakim H, Shune L, Abdallah AO, Singh AK, Abhyankar SH, McGuirk JP, Mushtaq MU. Favorable outcomes following CD34-selected stem cell boost for poor graft function after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2024 Jan.59(1):134-137. Pubmedid: 37833526.
• Shahzad M, Khan MA, Amin MK, Sarfraz Z, Zulfiqar F, Qasim H, Bansal R, Brownback K, Ahmed N, Abhyankar SH, McGuirk JP, Singh AK, Mushtaq MU. Efficacy of Ruxolitinib with corticosteroids in idiopathic pneumonia syndrome post-allogeneic hematopoietic stem cell transplantation: A single-center experience and systematic review. Transpl Immunol. 2024 Dec.87:102135. Pubmedid: 39368752.
• Park R, Yu J, Shahzad M, Lee S, Ji JD. The immune regulatory function of B7-H3 in malignancy: spotlight on the IFN-STAT1 axis and regulation of tumor-associated macrophages. Immunol Res. 2024 Aug.72(4):526-537. Pubmedid: 38265550.
• Shahzad M, Amin MK, Bellman P, Al-Ramahi J, Noor J, Vyas A, Mahmoudjafari Z, McGuirk M, DeJarnette S, Ahmed N, Abdallah AO, Shune L, Singh AK, McGuirk JP, Abhyankar S, Mushtaq MU. Comparison of biosimilar filgrastim and originator filgrastim for peripheral blood stem cell mobilization for allogeneic hematopoietic stem cell transplantation. Transfusion. 2024 Aug.64(8):1402-1406. Pubmedid: 38847196.
• Mushtaq MU, Shahzad M, Amin MK, Lutfi F, DeJarnette S, Al-Ramahi JS, Li K, Ahmed N, Bansal R, Abdelhakim H, Shune L, Abdallah AO, Abhyankar SH, McGuirk JP, Singh AK. Outcomes with HLA-matched unrelated donor versus haploidentical hematopoietic cell transplantation. Leuk Lymphoma. 2024 Apr.65(4):493-502. Pubmedid: 38164945.
• Bellman P, Gonzalez-Lugo JD, Shahzad M, Amin MK, Khalid MF, Suleman N, Ahmed N, Singh AK, Yacoub A, Zhang D, McGuirk JP, Mushtaq MU. Successful treatment with fludarabine and cyclophosphamide in a VEXAS syndrome patient with associated myelodysplastic syndrome: a case report and systematic review. Front Oncol. 2024 Apr.14:1383730. Pubmedid: 38665946. Pmcid: PMC11043578.
• Shahzad M, Iqbal Q, Tariq E, Ammad-Ud-Din M, Butt A, Mushtaq AH, Ali F, Chaudhary SG, Anwar I, Gonzalez-Lugo JD, Abdelhakim H, Ahmed N, Hematti P, Singh AK, McGuirk JP, Mushtaq MU. Outcomes with allogeneic hematopoietic stem cell transplantation in TP53-mutated myelodysplastic syndrome: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2024 Apr.196:104310. Pubmedid: 38423375.
• Ammad Ud Din M, Saeed H, Shahzad M, Liaqat H, Sweet K. The impact of mild-to-moderate chronic kidney disease on hospitalization outcomes in patients with acute myeloid leukemia. Leuk Lymphoma. 2023 May.64(5):1040-1044. Pubmedid: 36938919.
• Ammad Ud Din M, Chowdhury M, Shahzad M, Liaqat H, Jaglal M. Increased risk of eclampsia and preeclampsia during delivery hospitalizations in women with beta-thalassemia; An analysis of the National Inpatient Sample database. Eur J Obstet Gynecol Reprod Biol X. 2023 Mar.17:100175. Pubmedid: 36590708. Pmcid: PMC9800251.
• Shahzad M, Hussain A, Tariq E, Anwar I, Faisal MS, Syed L, Karam A, Chaudhary SG, Ahmed N, Bansal R, Khurana S, Singh AK, Byrd KP, Hematti P, Abhyankar SH, McGuirk JP, Mushtaq MU. Outcomes of Tyrosine Kinase Inhibitors Maintenance Therapy with or without Allogeneic Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in First Complete Remission: A Systematic Review and Meta-Analys. Clin Lymphoma Myeloma Leuk. 2023 Mar.23(3):178-187. Pubmedid: 36682989.
• Ammad Ud Din M, Jaan A, Shahzad M, Liaqat H, McGuirk J, Mushtaq MU. Poor hospitalization outcomes in patients undergoing allogeneic hematopoietic stem cell transplant with hospital acquired influenza infection. Transpl Infect Dis. 2023 Jun.25(3):e14066. Pubmedid: 37129229.
• Ammad Ud Din M, Chowdhury M, Shahzad M, Zahid S, Liaqat H, Osama M, Elmariah H. Trends and in-hospital cardiac complications in patients with atrial fibrillation undergoing allogeneic stem cell transplant: A National Inpatient Sample analysis (2002-2019). Eur J Haematol. 2023 Jun.110(6):754-761. Pubmedid: 36949272.
• Shahzad M, Chaudhary SG, Tariq E, Mushtaq AH, Anwar I, Ahmed N, Bansal R, Lutfi F, Balusu R, Abdelhakim H, Yacoub A, Hematti P, Singh AK, McGuirk JP, Mushtaq MU. Use of endpoints in phase III randomized controlled trials for acute myeloid leukemia over the last 15 years: a systematic review. Leuk Lymphoma. 2023 Feb.64(2):273-282. Pubmedid: 36282773.
• Al-Ramahi JS, Shahzad M, Li K, DeJarnette S, Chaudhary SG, Lutfi F, Ahmed N, Balusu R, Bansal R, Abdelhakim H, Shune L, Singh AK, Abhyankar SH, McGuirk JP, Mushtaq MU. Lessons learned from COVID-19 pandemic: outcomes after SARS-CoV-2 infection in hematopoietic cell transplant and cell therapy recipients. Leuk Lymphoma. 2023 Dec.64(12):1981-1991. Pubmedid: 37574842.
• Ammad Ud Din M, Shahzad M, Ashraf A, Liaqat H, Jaan A, Anwer F. Clinical Research in Chronic Lymphocytic Leukemia in Pakistan; A Systematic Review. Medicina (Kaunas). 2023 Aug.59(8). Pubmedid: 37629773. Pmcid: PMC10456454.
• Ammad Ud Din M, Mahmud A, Mostafa M, Shahzad M, Liaqat H, Pinilla-Ibarz J, Jaglal M. Risks and outcomes of hospitalizations in patients with chronic lymphocytic leukemia admitted with immune thrombocytopenia: an analysis of the National Inpatient Sample Database. Ann Hematol. 2023 Apr.102(4):889-895. Pubmedid: 36781419.
• Shahzad M, Nguyen A, Hussain A, Ammad-Ud-Din M, Faisal MS, Tariq E, Ali F, Butt A, Anwar I, Chaudhary SG, Lutfi F, Ahmed N, Singh AK, Hematti P, McGuirk JP, Mushtaq MU. Outcomes with chimeric antigen receptor t-cell therapy in relapsed or refractory acute myeloid leukemia: a systematic review and meta-analysis. Front Immunol. 2023 Apr.14:1152457. Pubmedid: 37168849. Pmcid: PMC10164930.
• Mushtaq MU, Shahzad M, Shah AY, Chaudhary SG, Zafar MU, Anwar I, Neupane K, Khalid A, Ahmed N, Bansal R, Balusu R, Singh AK, Abhyankar SH, Callander NS, Hematti P, McGuirk JP. Impact of natural killer cells on outcomes after allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis. Front Immunol. 2022 Oct.13:1005031. Pubmedid: 36263054. Pmcid: PMC9574024.
• Mushtaq MU, Shahzad M, Tariq E, Iqbal Q, Chaudhary SG, Zafar MU, Anwar I, Ahmed N, Bansal R, Singh AK, Abhyankar SH, Callander NS, Hematti P, McGuirk JP. Outcomes with mismatched unrelated donor allogeneic hematopoietic stem cell transplantation in adults: A systematic review and meta-analysis. Front Oncol. 2022 Oct.12:1005042. Pubmedid: 36276084. Pmcid: PMC9583270.
• Khanam R, Shahzad M, Chaudhary SG, Ali F, Shah Z, Pachika PS, Ahmed Z, Chattaraj A, Masood A, Ahmed N, Bansal R, Balusu R, Shune L, Anwar F, Hematti P, McGuirk JP, Yacoub A, Mushtaq MU. Outcomes after venetoclax with hypomethylating agents in myelodysplastic syndromes: a systematic review and meta-analysis. Leuk Lymphoma. 2022 Nov.63(11):2671-2678. Pubmedid: 35687838.
• Siddiqui RS, Chaudhary SG, Shahzad M, Anwar I, Hussain A, Ahmed N, Abhyankar SH, Shune L, Hematti P, Male H, Khosa F, Lin T, McGuirk JP, Callander NS, Mushtaq MU. Gender disparities in the National Institutes of Health funding for hematologic malignancies and cellular therapies. Leuk Lymphoma. 2022 Jul.63(7):1708-1713. Pubmedid: 35142581.
• Shahzad M, Chaudhary SG, Anwar I, Arslan M, Naseem Z, Fatima NT, Abbas S, Ali T, Siddiqui RS, Hematti P, Abhyankar SH, McGuirk JP, Mushtaq MU. Top 100 Cited Articles on Clinical Hematopoietic Stem Cell Transplantation: A Bibliometric Analysis. Front Med (Lausanne). 2022 Jul.9:872692. Pubmedid: 35733859. Pmcid: PMC9208296.
• Ahmed N, Shahzad M, Shippey E, Bansal R, Mushtaq MU, Mahmoudjafari Z, Faisal MS, Hoffmann M, Abdallah AO, Divine C, Hamadani M, McGuirk J, Shune L. Socioeconomic and Racial Disparity in Chimeric Antigen Receptor T Cell Therapy Access. Transplant Cell Ther. 2022 Jul.28(7):358-364. Pubmedid: 35429662.
• Shahzad M, Chaudhary SG, Basit A, Thellman C, Rodriguez L, Abhyankar SH, McGuirk JP, Mushtaq MU. Chronic graft-versus-host disease presenting as acute polymyositis: A case series and systematic review. Transpl Immunol. 2022 Feb.70:101520. Pubmedid: 34952168.
• Shahzad M, Tariq E, Chaudhary SG, Anwar I, Iqbal Q, Fatima H, Abdelhakim H, Ahmed N, Balusu R, Hematti P, Singh AK, McGuirk JP, Mushtaq MU. Outcomes with allogeneic hematopoietic stem cell transplantation in TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis. Leuk Lymphoma. 2022 Dec.63(14):3409-3417. Pubmedid: 36107118.
• Shahzad M, Chaudhary SG, Zafar MU, Hassan MA, Hussain A, Ali F, Anwar I, Ahmed M, Ahmed N, Khurana S, Rauf MA, Anwar F, Hematti P, Callander NS, Abhyankar SH, McGuirk JP, Mushtaq MU. Impact of COVID-19 in hematopoietic stem cell transplant recipients: A systematic review and meta-analysis. Transpl Infect Dis. 2022 Apr.24(2):e13792. Pubmedid: 35030267.
• Mushtaq MU, Shahzad M, Chaudhary SG, Luder M, Ahmed N, Abdelhakim H, Bansal R, Balusu R, DeJarnette S, Divine C, Kribs R, Shune L, Singh AK, Ganguly S, Abhyankar SH, McGuirk JP. Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients. Transplant Cell Ther. 2021 Sep.27(9):796.e1-796.e7. Pubmedid: 34256172. Pmcid: PMC8272625.
• Shahzad M, Siddiqui RS, Anwar I, Chaudhary SG, Ali T, Naseem M, Ahmed TF, Ahmed Z, Khurana S, Ahmed N, Balusu R, Singh AK, Hematti P, Callander NS, Abhyankar SH, McGuirk JP, Mushtaq MU. Outcomes with CD34-Selected Stem Cell Boost for Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. Transplant Cell Ther. 2021 Oct.27(10):877.e1-877.e8. Pubmedid: 34284148.
• Siddiqui R, Sardar M, Shahzad M, Jose J, Selene I, Shah Z, Qureshi A, Shafqat M, Kashif R, Ahmad M, Mejia-Garcia A, Anwer F. Management of Relapsed Hairy Cell Leukemia: A Systematic Review of Novel Agents and Targeted Therapies. Clin Lymphoma Myeloma Leuk. 2021 Oct.21(10):659-666. Pubmedid: 34275772.
• Sarwar A, Hashim L, Faisal MS, Haider MZ, Ahmed Z, Ahmed TF, Shahzad M, Ansar I, Ali S, Aslam MM, Anwer F. Advances in viral oncolytics for treatment of multiple myeloma - a focused review. Expert Rev Hematol. 2021 Dec.14(12):1071-1083. Pubmedid: 34428997.
• Ditah CM, Rahman E, Agbor VN, Foryoung JB, Shahzad M, Amgai B, Kafle P, Jonnadula S, Nfor TK, Dufresne A. Disparities and drivers of early age at diagnosis of congestive heart failure in the USA. Int J Cardiol. 2019 Oct.293:143-147. Pubmedid: 31230932.